QUICK READ: Those of us in the industry know that ANY information that comes from Gilead should be questioned. There was only one objective of these trails and that was to increase sales of Remdesivir.
Gilead
QUICK READ: Via the FT “Gilead Sciences has come under fire for securing a de facto monopoly in the US for an experimental drug seen as a potential coronavirus treatment, with activists accusing the US drugmaker of “morbid calculus” and “the most blatant abuse of the orphan drug act”. This company is a stain on the industry.
- A month’s supply of Truvada costs roughly $6 to make and sells for more than $1,600 in the United States.
- Truvada was developed largely with taxpayer dollars.
- Gilead has earned $36.2 billion on Truvada since 2004, according to its annual reports.